The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters.

	Quarter Ended
	December 31,				September 30,			June 30,			March 31,
(In thousands, except per share amounts)	2017 ⁽¹⁾				2017 ⁽¹⁾			2017			2017
Revenue	$	517,334			$	449,442		$	426,091		$	413,475
Cost of revenue		303,235				247,523			238,600			234,823
Gross profit		214,099				201,919			187,491			178,652
Selling, general and administrative expenses		146,037				117,352			112,037			110,845
Research and development		73,471				51,057			46,459			49,232
Asset impairment charges		0				0			0			0
Amortization of intangible and acquisition-related assets		10,414				8,137			7,891			7,312
Income from operations		(15,823	)			25,373			21,104			11,263
Interest expense		(24,757	)			(22,252	)		(20,290	)		(20,180	)
Other income (expense), net		958				(570	)		(214	)		239
Impairment of and losses on long-term investments		0				(20,700	)		(144,590	)		0
Equity in net income (loss) of unconsolidated investments		115				449			(28	)		285
Loss from continuing operations before income taxes		(39,507	)			(17,700	)		(144,018	)		(8,393	)
Income tax benefit (provision)		49,694		⁽²⁾		238			1,007			(172	)
Income (loss) from continuing operations, net of tax		10,187				(17,462	)		(143,011	)		(8,565	)
Income from discontinued operations, net of tax		4,676				0			0			0
Net income (loss)		14,863				(17,462	)		(143,011	)		(8,565	)
Less: Net loss (income) attributable to non-controlling interest		1,918				(163	)		264			(453	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(10,963	)			(10,962	)		(10,963	)		(10,962	)
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	5,818			$	(28,587	)	$	(153,710	)	$	(19,980	)

Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share:
Basic
Continuing operations	$	0.00			$	(0.16	)	$	(0.85	)	$	(0.11	)
Discontinued operations	$	0.03			$	0.00		$	0.00		$	0.00
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$	0.03			$	(0.16	)	$	(0.85	)	$	(0.11	)

Diluted
Continuing operations	$	0.00			$	(0.16	)	$	(0.85	)	$	(0.11	)
Discontinued opererations	$	0.03			$	0.00		$	0.00		$	0.00
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$	0.03			$	(0.16	)	$	(0.85	)	$	(0.11	)

	Quarter Ended
	December 31,				September 30,				June 30,				March 31,
(In thousands, except per share amounts)	2016 ⁽³⁾				2016 ⁽³⁾				2016 ⁽³⁾				2016
Revenue	$	425,436			$	392,384			$	386,521			$	345,558
Cost of revenue		239,138				226,225				219,837				193,660
Gross profit		186,298				166,159				166,684				151,898
Selling, general and administrative expenses		115,132				98,778				94,802				84,153
Research and development		47,836				45,142				47,891				47,037
Asset impairment charges		0				0				0				4,650
Amortization of intangible and acquisition-related assets		10,903				5,365				5,417				4,162
Income from operations		12,427				16,874				18,574				11,896
Interest expense		(25,384	)	⁽⁵⁾		(19,367	)			(16,421	)			(6,969	)
Other income (expense), net		621				(6	)			106				366
Equity in net loss of unconsolidated investments		0				0				(4,898	)			(2,603	)
(Loss) income before income taxes		(12,336	)			(2,499	)			(2,639	)			2,690
Income tax benefit (provision)		15,218		⁽⁴⁾		2,656		⁽⁴⁾		503		⁽⁴⁾		(563	)	⁽⁴⁾
Net income (loss)		2,882				157				(2,136	)			2,127
Less: Net (income) loss attributable to non-controlling interest		(4	)			(151	)			87				(78	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(10,192	)			(10,191	)			(8,153	)			0
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(7,314	)		$	(10,185	)		$	(10,202	)		$	2,049
(Loss) earnings per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.04	)		$	(0.06	)		$	(0.05	)		$	0.01

⁽¹⁾	Results of operations for the quarter include the results of operations of (i) DeVero since July 17, 2017, (ii) the provider and patient engagement business of NantHealth since August 25, 2017 and (iii) the results of operations of the EIS Business since October 2, 2017.

⁽²⁾	Income tax benefit (provision) for the quarter ended December 31, 2017, reflects the estimated impact of the United States Tax Cuts and Jobs Act which was enacted on December 22, 2017 and introduced significant changes to the income tax law in the United States.

⁽³⁾

Results of operations for the quarter include the results of operations of (i) Netsmart since April 19, 2016, (ii) HealthMEDX since October 27, 2016, and (iii) the results of operations of three third parties in which we acquired a controlling interest during the quarters ended September 30^th December 31^st, 2016 from the date of each acquisition.

⁽⁴⁾

Income tax benefit (provision) reflects the recognition (release) of a valuation allowance of ($14.3) million, ($3.3) million, $0.9 million and ($0.9) million for federal credit carryforwards, and foreign and state net operating loss carryforwards in the quarters ended December 31, 2016, September 30, 2016, June 30, 2016, and March 31, 2016, respectively.

⁽⁵⁾

Interest expense includes the write-off of $5.2 million deferred debt issuance costs in connection with Netsmart’s amendment of its First Lien Credit Agreement during the quarter ended December 31, 2016 and the write-off of $1.4 million of deferred debt issuance costs in connection with amending the Senior Secured Credit Facility during the quarter ended September 30, 2015.